E3 PreliminaryPreliminaryPEM unclearMethods-PaperPeer-reviewedMachine draft
Characterization of antibodies elicited by XMRV infection and development of immunoassays useful for epidemiologic studies.
Qiu, Xiaoxing, Swanson, Priscilla, Luk, Ka-Cheung et al. · Retrovirology · 2010 · DOI
Quick Summary
Researchers studied how the body's immune system responds to XMRV infection by infecting three monkeys and tracking antibodies (immune markers) over time. They found that infected animals developed detectable antibodies within two weeks and created three new blood tests to reliably detect XMRV infection, which could help researchers study whether XMRV is connected to ME/CFS.
Why It Matters
This work addresses a critical methodological need for XMRV epidemiological research in ME/CFS by providing validated, high-throughput assays to detect XMRV infection at scale. If XMRV is confirmed as an ME/CFS pathogen, these reliable detection methods would enable large population studies needed to establish prevalence, transmission patterns, and clinical associations.
Observed Findings
- All three infected macaques developed XMRV-specific antibodies by week 2 of infection
- Antibodies to envelope protein gp70 and transmembrane protein p15E appeared early with higher titers than capsid protein p30
- Antibodies to all three viral proteins persisted for at least 158 days post-infection and were substantially boosted by re-infection
- gp70 and p15E assays achieved 100% sensitivity in detecting infected animals and 99.5-99.9% specificity in blood donors
- p30 assay demonstrated 92% seroconversion sensitivity and 99.4% specificity
Inferred Conclusions
- gp70, p15E, and p30 are reliable serologic markers for XMRV infection detection
- The three developed prototype immunoassays have adequate sensitivity and specificity to facilitate large-scale human epidemiologic studies of XMRV
- XMRV infection elicits a measurable antibody response with characteristic kinetics suitable for diagnostic testing
Remaining Questions
- Do these assays perform with equivalent sensitivity and specificity in human populations compared to primate models?
- Do XMRV-seropositive ME/CFS patients show the same antibody kinetics and immune response patterns observed in this primate model?
What This Study Does Not Prove
This study does not prove that XMRV causes ME/CFS or is even present in ME/CFS patients—it only develops and validates tools for detecting XMRV antibodies in primates. The findings do not establish whether antibody presence indicates active infection, past infection, or clinical disease, nor do they address XMRV prevalence or pathogenic mechanisms in humans.
Tags
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:No ControlsSmall SampleExploratory Only
Metadata
- DOI
- 10.1186/1742-4690-7-68
- PMID
- 20716359
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →